Physician profile
Douglas Ansert
NPI 1699017038
$3,515.36
in general payments reported to CMS, 2019-2025
27 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $454 · 2021: $579 · 2022: $262 · 2023: $232 · 2024: $434 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658 · Education: $34.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.28 |
| Education | $34.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $671.31 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $456.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $395.49 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $292.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $227.55 | 2020-2021 | |
| Glaxosmithkline, LLC. | $189.35 | 2019-2025 | Bexsero, Arexvy, Shingrix |
| Pfizer INC. | $177.43 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.05 | 2019-2021 | |
| Amgen INC. | $124.47 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $108.92 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $99.36 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.95 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $85.47 | 2022 | |
| Supernus Pharmaceuticals, INC. | $75.80 | 2021-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $74.04 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.24 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $43.81 | 2019-2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $32.50 | 2024-2025 | |
| Cranial Technologies, INC | $28.07 | 2024 | Doc Band |
| Alexion Pharmaceuticals, INC. | $26.23 | 2022 | |
| Sanofi Pasteur INC. | $25.23 | 2024 | |
| Medtronic, INC. | $20.27 | 2025 | Synchromedii |
| Hologic Sales and Service, LLC | $19.37 | 2025 | Aptima |
| Sanofi-Aventis U.S. LLC | $18.16 | 2025 | |
| Phathom Pharmaceuticals, INC. | $17.02 | 2025 | Voquezna |
| Misonix INC | $14.33 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Ansert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.